

## ZÁVĚR

Dostupná data potvrzují nízké, ale reálné riziko ovlivnění kognitivního výkonu a rozvoje demence při

dlouhodobé expozici anticholinergikům používaným v léčbě OAB. Vždy bychom proto měli pečlivě zvažovat poměr mezi očekávaným benefitem a potenciálními riziky v případě konkrétního pacienta.

## LITERATURA

1. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. *J Am Geriatr Soc.* 2011; 59(8): 1477–1483.
2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Int Urogynecol J.* 2010; 21(1): 5–26.
3. Peyronnet B, Mironska E, Chapple C, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. *Eur Urol.* 2019; 75(6): 988–1000.
4. Nambiar AK, Arlandis S, Bø K, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. *Eur Urol.* 2022; 82(1): 49–59.
5. He W, Huang G, Cui W, et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. *Int Braz J Urol.* 2023; 49(5): 535–563.
6. Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. *Neurourol Urodyn.* 2019; 38(2): 525–534.
7. Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. *PLoS One.* 2011 Feb 23; 6(2): e16718.
8. Kim YJ, Tae BS, Bae JH. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. *Int Neurourol J.* 2020; 24(3): 231–240.
9. Morley JE, Morris JC, Berg-Weger M, et al. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. *J Am Med Dir Assoc.* 2015; 16(9): 731–739.
10. Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study. *Alzheimers Dement.* 2019; 15(1): 1–7.
11. Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. *Ann Neurol.* 2011; 70(3): 418–426.
12. Tiwari P, Dwivedi S, Singh MP, Mishra R, Chandy A. Basic and modern concepts on cholinergic receptor: A review. *Asian Pac J Trop Dis.* 2013; 3(5): 413–420.
13. Lebois EP, Thorn C, Edgerton JR, Popielek M, Xi S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. *Neuropharmacology.* 2018; 136(Pt C): 362–373.
14. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev.* 1998; 50(2): 279–290.
15. Brann MR, Ellis J, Jørgensen H, Hill-Eubanks D, Jones SV. Muscarinic acetylcholine receptor subtypes: localization and structure/function. *Prog Brain Res.* 1993; 98: 121–127.
16. Messer WS Jr, Bohnett M, Stibbe J. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. *Neurosci Lett.* 1990; 116(1–2): 184–189.
17. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol.* 2006; 148(5): 565–78.
18. Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. *Int Urogynecol J.* 2021; 32(10): 2693–2702.